and neuroendocrine responses to water immersion in compensated heart failure. Am J Physiol Heart Circ Physiol 279: H1931-H1940, 2000.-The hypothesis was tested that cardiovascular and neuroendocrine (norepinephrine, renin, and vasopressin) responses to central blood volume expansion are blunted in compensated heart failure (HF). Nine HF patients [New York Heart Association class II-III, ejection fraction ϭ 0.28 Ϯ 0.02 (SE)] and 10 age-matched controls (ejection fraction ϭ 0.68 Ϯ 0.03) underwent 30 min of thermoneutral (34.7 Ϯ 0.02°C) water immersion (WI) to the xiphoid process. WI increased (P Ͻ 0.05) central venous pressure by 3.7 Ϯ 0.6 and 3.2 Ϯ 0.4 mmHg and stroke volume index by 12.2 Ϯ 2.1 and 7.2 Ϯ 2.1 ml ⅐ beat Ϫ1 ⅐ m Ϫ2 in controls and HF patients, respectively. During WI, systemic vascular resistance decreased (P Ͻ 0.05) similarly by 365 Ϯ 66 and 582 Ϯ 227 dyn ⅐ s ⅐ cm Ϫ5 in controls and HF patients, respectively. Forearm subcutaneous vascular resistance decreased by 19 Ϯ 7% (P Ͻ 0.05) in controls but did not change in HF patients. Heart rate decreased less during WI in HF patients, whereas release of norepinephrine, renin, and vasopressin was suppressed similarly in the two groups. We suggest that reflex control of forearm vascular beds and heart rate is blunted in compensated HF but that baroreflex-mediated systemic vasodilatation and neuroendocrine responses to central blood volume expansion are preserved. sympathetic nervous activity; arginine vasopressin; reninangiotensin system; endothelin; baroreceptors REGULATION OF CARDIOVASCULAR and neuroendocrine variables in heart failure (HF) has primarily been investigated by utilizing orthostatic stress to decrease central blood volume. Results of these investigations (19, 20, 27, 30, 33, 34, 43) indicate that the neuroendocrine and vasoconstrictor responses to orthostatic maneuvers are abnormal in HF. Therefore, baroreflex regulation of vascular resistance and sympathetic nervous activity and modulation of hormonal vasoconstrictor activity [renin-angiotensin system, arginine vasopressin (AVP), and endothelins] may also be compromised in HF patients in response to central blood volume expansion and baroreceptor loading (21).
REGULATION OF CARDIOVASCULAR and neuroendocrine variables in heart failure (HF) has primarily been investigated by utilizing orthostatic stress to decrease central blood volume. Results of these investigations (19, 20, 27, 30, 33, 34, 43) indicate that the neuroendocrine and vasoconstrictor responses to orthostatic maneuvers are abnormal in HF. Therefore, baroreflex regulation of vascular resistance and sympathetic nervous activity and modulation of hormonal vasoconstrictor activity [renin-angiotensin system, arginine vasopressin (AVP), and endothelins] may also be compromised in HF patients in response to central blood volume expansion and baroreceptor loading (21) .
Seated thermoneutral (34.5-35 .0°C) water immersion (WI) is a recognized model to induce isosmotic central volume expansion in humans (13) . In healthy subjects, WI induces a prompt and sustained increase in central blood volume (13, 41) accompanied by loading of cardiopulmonary and arterial baroreceptors (16, 39, 41) . Concomitantly, sympathetic nervous activity and systemic vascular resistance decrease and AVP release and the renin-angiotensin-aldosterone axis are suppressed (13, 23, 36, 41) .
It is generally accepted that elevated plasma levels of AVP, angiotensin II (ANG II), endothelin-1 (ET-1), and sympathetic nervous activity induce vasoconstriction and sodium and water retention in HF (40) , leading to volume overload and an increase in cardiac filling pressures. If baroreflex function is impaired in HF, this could prevent or attenuate the modulation of sympathetic nervous activity and release of vasoconstrictor hormones and the decrease in systemic vascular resistance in response to an increase in central blood volume.
Medical treatment of patients with severe HF often causes symptomatic relief and improves cardiac function. These patients can then be kept in a compensated state with a more moderate degree of cardiac dysfunction. When treatment is withdrawn for longer periods, these patients again develop disturbances of neuroendocrine control mechanisms. The question is whether the neuroendocrine dysregulation in response to an increase in central blood volume persists in a compensated state of HF and whether chronic impairment of the baroreflex-mediated responses to central blood vol-ume expansion contributes to the abnormalities. Therefore, the purpose of this investigation was to assess the cardiovascular and neuroendocrine [AVP, plasma renin activity (PRA), ANG II, ET-1, and catecholamines] responses to an increase in central blood volume in compensated HF.
Apparently, thermoneutral WI has not previously been used as a tool to investigate baroreflex-mediated control of the circulation and the release of vasoconstrictor hormones in compensated HF. Therefore, we utilized this approach to test the hypothesis that suppression of the neuroendocrine vasoconstrictor systems is attenuated in compensated HF in response to WIinduced central hypervolemia.
METHODS
Subjects. Nine outpatients with HF (evaluated for cardiac transplantation) in a stable compensated phase and with low ejection fractions [New York Heart Association functional class (NYHA) II, n ϭ 7; NYHA III, n ϭ 2] and 10 age-and gender-matched control subjects were included in the study (Table 1 ). All patients exhibited dilated cardiomyopathy (idiopathic, n ϭ 6; ischemic, n ϭ 3). In addition to routine clinical and echocardiographic evaluation, the diagnosis was based on pretransplant invasive cardiac evaluation in eight of the patients. The average duration of HF symptoms was 51 mo (range 9-150 mo). The patients had no present history of angina pectoris or recent (Ͻ3 mo) history of myocardial infarction and were without signs of decompensation (pulmonary rales and peripheral edema) on the day of the study. They were on standard medical treatment with angiotensinconverting enzyme (ACE) inhibitors (n ϭ 8), diuretics (n ϭ 8), and digoxin (n ϭ 7). In addition, three HF patients received nitrate vasodilator therapy, one received an ␣/␤-adrenoreceptor blocker (carvedilol), and one received a ␤ 1 -adrenoreceptor blocker (metoprolol). ACE inhibitors were discontinued 24 h before the study, and all other medications were withheld on the day of the study. All subjects were in sinus rhythm at the time of the study, except one HF patient with atrial fibrillation. Another HF patient had short-lasting non-insulin-dependent diabetes mellitus (Ͻ2 mo) treated by dietary restraint. Control subjects were healthy as indicated by medical history, clinical examination, normal blood pressure (Ͻ140/95 mmHg), normal hematocrit, and urine dip stick test. All participants gave written informed consent.
The experimental protocol was approved by the Ethical Committee of Copenhagen (KF 01-099/97) and was in agreement with institutional guidelines and the principles set forth in the Declaration of Helsinki.
Experimental protocol. Within 1 wk before the study, echocardiographic examination was carried out to determine cardiac functional status. For 3 days before the investigation, the participants ingested a standardized sodium-restricted diet containing 1 mmol sodium ⅐ kg body wt Ϫ1 ⅐ day
Ϫ1
. For 24 h before the experiment, urine was collected for determinations of sodium and potassium excretion. The subjects were instructed to abstain from eating, drinking, and smoking from 2200 on the evening before the experiment until its termination.
The subject arrived at the laboratory at 0730. A central venous catheter was introduced through an antecubital vein. For Ն30 min before the start of the experiment, the subject was seated upright in a chair above the immersion tank.
The experimental protocol consisted of two sessions separated by 30 min. The first session consisted of 30 min of seated control outside the water (baseline), 30 min of WI (34.7 Ϯ 0.02°C) to the xiphoid process, and then 30 min of seated recovery outside the water (recovery). The chair with the subject could be lowered and elevated into and out of the water tank by means of an electric hoist fastened to the ceiling. The second session consisted of 90 min of seated control outside the water with similar experimental procedures.
One HF patient developed vasovagal-mediated hypotension during the seated control study; therefore, the data from this session have been omitted from the analysis. Thus 9 HF patients were included in the immersion session and 8 in the seated control, and 10 healthy controls were included in both experimental sessions.
Air temperature and humidity were kept at 26.8 Ϯ 0.1°C (SE) and 47 Ϯ 2%, respectively, during the immersion session and at 27.1 Ϯ 0.1°C and 45 Ϯ 2%, respectively, during seated control.
Measurements. Central venous pressure (CVP; HF, n ϭ 8; controls, n ϭ 10) was measured using a fluid-filled catheter (Cavafix, Braun), with the transducer (model DT-XX, ROSE, BOC Ohmeda) reference set at the sternal border of the fourth intercostal space during all times of the experiment. The intrathoracic location of the catheter tip was demonstrated by observing characteristic waveforms and responses to respiratory maneuvers.
Left atrial diameter (LAD; HF, n ϭ 9; controls, n ϭ 8) was measured every 15 min (model ssd-500, Aloka) from three M-mode recordings obtained from the parasternal long-axis view. Printouts of the recordings were analyzed manually by the same investigator in a blinded fashion by use of the criteria described by Feigenbaum (14) .
Arterial blood pressure in the brachial artery was measured by sphygmomanometry, with the cuff kept at the same position relative to the heart during all measurements. Arterial pulse pressure was calculated from systolic Ϫ diastolic arterial pressure, and mean arterial pressure was calculated from diastolic pressure ϩ one-third of the pulse pressure.
Cardiac output (HF, n ϭ 6; controls, n ϭ 8) was derived from measurements of pulmonary blood flow by use of an inert gas rebreathing method, as previously described (3, 4) . Briefly, a closed system containing a rebreathing gas mixture of 1% SF 6 , 5% N 2 O, and 50% O 2 in N 2 and an infrared photoacoustic gas analyzer (model AMIS 2001, Innovision, Odense, Denmark) was used. Rebreathings were performed over 34 s with a gas volume of 30% of the calculated vital capacity and a breathing rate of 14 min Ϫ1 . Pulmonary blood flow was then determined from the gas concentration traces (3, 4) . From these measurements, stroke volume, cardiac Values are means Ϯ SE of 9 HF patients and 10 controls, unless otherwise noted. HF, heart failure; U Na V, urinary sodium excretion; Hct, hematocrit; LAD, prestudy left atrial diameter; LVEDD, prestudy left ventricular end-diastolic diameter; LVEF, prestudy left ventricular ejection fraction. LAD, LVEDD, and LVEF were determined by echocardiography in the left lateral decubitus position. * n ϭ 8; † n ϭ 7.
index, stroke volume index, and systemic vascular resistance were calculated using standard formulas. The intraindividual coefficient of variation (CV) of the calculated systemic vascular resistance was determined from the consecutive measurements during the 90-min seated control study. The CV was 8.5 Ϯ 1% (SE) in controls and 8.4 Ϯ 0.5% in HF patients.
Single-lead electrocardiogram and arterial pressure in an index finger (Finapres 2300, Ohmeda) were sampled on a computer, and heart rate and finger mean arterial pressure (electronic) were determined subsequently. Finger mean arterial pressure was continuously measured on the same arm as the 133 Xe washout measurements and regarded as forearm perfusion pressure, since forearm venous pressure does not change during WI (9) . Because brachial arterial pressure was measured at heart level and mean finger arterial pressure was measured in the elevated arm (to prevent contact with the water), there was a hydrostatic difference of ϳ20 cm between the two sites of arterial pressure measurement. This is the explanation for the systematic difference in the two different measurements of arterial pressure ( Table 2 ). The local forearm subcutaneous and muscle vascular resistances were calculated as finger mean arterial pressure Ϭ regional blood flow.
Forearm subcutaneous (2 cm proximal to the wrist) and skeletal muscle (proximal brachioradial muscle) blood flows were measured continuously using the 133 Xe washout technique (29) . Briefly, the subject received local injections of 133 Xe (Amersham International, Amersham, Bucks, UK) dissolved in saline, and the counting rate was then recorded by means of stationary NaI detectors (adjusted to the 81-keV photopeak of 133 Xe) and stored on a computer. The isotope 
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Values are means Ϯ SE of 9 HF patients and 10 controls (Con) unless otherwise noted. SAP, systolic arterial pressure; DAP, diastolic arterial pressure; MAP, mean arterial pressure; PP, arterial pulse pressure; HR, heart rate; CI, cardiac index; Epi, epinephrine; ET-1, endothelin-1; FSBF, forearm subcutaneous blood flow; FMBF, forearm skeletal muscle blood flow. * Statistically significant change (P Ͻ 0.05) from average of baseline measurements; † statistically significant difference (P Ͻ 0.05) between average HF values of baseline, water immersion, or recovery, respectively, and Con. ‡ n ϭ 6; § n ϭ 8.
injections were performed Ն30 min before the start of the measurements to minimize the influence of the injection trauma (29) . The washout rates (k, min Ϫ1 ) were determined as the slope (regression line by use of the least-square method) of the logarithmically transformed counting rates plotted against time. Blood flow (f ) is proportional to k by the following equation: f ϭ k ⅐ ⅐ 100 ml ⅐ 100 g Ϫ1 ⅐ min Ϫ1 , where is the tissue-to-blood partition coefficient ( of 133 Xe ϭ 0.7 ml/g in skeletal muscle tissue and 10 ml/g in subcutaneous tissue). Regional forearm subcutaneous and skeletal muscle blood flows were determined as averages over consecutive 15-min periods. The 133 Xe washout technique probably underestimates true muscle blood flow, but changes in blood flow can be correctly estimated (17, 29) . The CV of forearm subcutaneous vascular resistance (during the 90-min seated control period) was 21 Ϯ 3% (SE) in controls and 23 Ϯ 5% in HF patients. The corresponding values for forearm skeletal muscle vascular resistance were 16 Ϯ 3% (controls) and 15 Ϯ 4% (HF patients).
Blood samples (20 ml) were drawn each 15 min from the central venous catheter, and the amount of sampled blood was substituted by isotonic saline. The blood was immediately transferred into chilled tubes and centrifuged at 3,700 rpm at 4°C for 10 min. The plasma was then frozen and stored at Ϫ25°C for later determinations of plasma concentrations of AVP, ANG II, ET-1, PRA, norepinephrine (NE), and epinephrine (Epi). AVP, ANG II, ET-1, and PRA were measured by RIA, and NE and Epi were measured by radioenzymatic assay, as previously described (11, 12, 26, 28, 38) . Plasma concentrations of protein (pocket refractometer, Bellingham & Stanley), sodium and potassium (model KNA-2, Radiometer), and plasma osmolality (Advanced Osmometer 3MO Plus) were measured in duplicate or triplicate on fresh samples.
Statistical analysis. Multifactor ANOVA corrected for repeated measures and a post hoc multiple range (NewmanKeuls) test were used to detect changes within groups from the average of the two baseline measurements over time during the WI or control sessions, respectively. During the 90-min seated control session, pooled data were used for comparison between groups. A two-sample t-test was used to detect differences in subject characteristics and the responses to WI for selected variables. Statistical evaluation of forearm subcutaneous and skeletal muscle vascular resistance was performed on absolute values but presented as relative changes. Data were logarithmically transformed before analysis if heterogeneity of variance was present. P Ͻ 0.05 was considered statistically significant. Values are means Ϯ SE.
RESULTS
Central hemodynamic responses to WI. During the seated baseline period, no differences in arterial pressures were observed between controls and HF patients ( Table 2 ). In response to WI, the control subjects exhibited an increase in systolic arterial pressure and pulse pressure (P Ͻ 0.05) compared with baseline values, whereas mean and diastolic arterial pressures did not change. In HF, systolic and mean arterial pressure increased during the last 15 min of immersion (P Ͻ 0.05) compared with baseline values with no changes in diastolic or pulse pressure.
CVP was similar at baseline in controls and HF patients and increased to the same extent in response to WI (P Ͻ 0.05; Fig. 1 ). LAD was significantly higher in HF patients (43 Ϯ 3 mm) than in controls (29 Ϯ 3 mm, P Ͻ 0.05 vs. HF; Fig. 2 ) and increased in both groups during WI (P Ͻ 0.05) compared with baseline values. The average increase in CVP was 3.7 Ϯ 0.6 mmHg in controls and 3.2 Ϯ 0.4 mmHg in HF patients (P ϭ 0.43 vs. controls). The corresponding values for LAD were 6.4 Ϯ 0.9 mm in controls and 6.1 Ϯ 1.1 mm in HF patients (P ϭ 0.53 vs. controls). The relative increase in LAD in response to central blood volume expansion, however, was less in HF patients (16 Ϯ 4%) than in controls (27 Ϯ 5%, P Ͻ 0.05 vs. HF), because the HF patients exhibited dilated cardiac chambers at , and during recovery (60-90 min) in patients with heart failure (HF) and control subjects (Con). Values are means Ϯ SE; n ϭ 8 HF patients and n ϭ 10 controls for CVP, n ϭ 9 HF patients and n ϭ 8 controls for LAD, and n ϭ 6 HF patients and n ϭ 8 controls for SVI. * Statistically significant change (P Ͻ 0.05) from the average of the baseline measurements; † statistically significant difference (P Ͻ 0.05) between average HF values of baseline, WI, or recovery and Con values.
baseline. Heart rate was substantially higher in HF patients than in controls (P Ͻ 0.05; Table 2 ). Heart rate decreased (P Ͻ 0.05) during WI in controls, whereas a statistically significant decrease could not be detected in HF patients (P ϭ 0.10).
Cardiac and stroke volume index increased in controls and HF patients in response to WI (P Ͻ 0.05) and returned to baseline during recovery (Table 2) . No differences between the groups were observed for cardiac index, whereas stroke volume index was significantly lower (P Ͻ 0.05) in HF patients than in controls. The average increase in cardiac index was 0.44 Ϯ 0.08 and 0.50 Ϯ 0.13 l ⅐ min Ϫ1 ⅐ m Ϫ2 in controls and HF patients, respectively (P ϭ 0.72 vs. controls). The corresponding increase in stroke volume index was 12.2 Ϯ 2.1 and 7.2 Ϯ 2.1 ml ⅐ beat Ϫ1 ⅐ m Ϫ2 in controls and HF patients, respectively (P ϭ 0.14 vs. controls).
Systemic vascular resistance decreased (P Ͻ 0.05) during WI in both groups and returned to baseline during recovery (Fig. 2) . The average decrease in systemic vascular resistance from the mean of the baseline measurements was 365 Ϯ 66 and 582 Ϯ 227 dyn ⅐ s ⅐ cm Ϫ5 in controls and HF patients, respectively (P ϭ 0.45 vs. controls). No differences in systemic vascular resistance were observed between the two groups.
Forearm vascular responses to WI. In the control group, there was a decrease (P Ͻ 0.05) in forearm subcutaneous vascular resistance during WI, and forearm muscle vascular resistance increased during recovery (P Ͻ 0.05; Fig. 2, Table 2 ). Forearm subcutaneous and muscle vascular resistance did not change in HF in response to WI or recovery.
Neuroendocrine responses to WI. Plasma concentration of AVP was higher (P Ͻ 0.05) in HF patients than in controls (Fig. 3) . During WI, plasma concentration of AVP decreased (P Ͻ 0.05) in both groups and returned to baseline levels during recovery. Plasma concentrations of ANG II were significantly higher in HF patients (P Ͻ 0.05) than in controls (Fig. 3) . In the control group, plasma ANG II concentrations were suppressed (P Ͻ 0.05) during WI, whereas WI did not cause a statistically significant suppression of plasma ANG II concentrations from baseline levels in HF patients (P ϭ 0.16). PRA was higher in HF patients (P Ͻ 0.05) than in controls and was suppressed in response to WI in both groups (P Ͻ 0.05; Fig. 3 ). Group differences were not observed for plasma concentrations of NE or Epi, and plasma concentrations of NE were suppressed in both groups in response to WI. Plasma concentrations of Epi were suppressed in controls during WI, whereas no statistically significant suppression of Epi from baseline levels was observed in HF patients (P ϭ 0.14).
No changes were observed in plasma concentrations of ET-1 during WI in either group (Table 2) .
Plasma composition during WI. Plasma sodium concentrations did not change in response to WI but were higher in controls (from 139 Ϯ 0.5 to 140 Ϯ 0.6 mmol/l) than in HF patients (from 136 Ϯ 1.4 to 137 Ϯ 1.2 mmol/l, P Ͻ 0.05 vs. controls).
Plasma osmolalities were similar in controls (from 286 Ϯ 0.9 to 287 Ϯ 1.0 mosmol/kg) and HF patients (from 284 Ϯ 2.5 to 286 Ϯ 2.7 mosmol/kg) and did not change during WI.
In both groups, there was a progressive decrease in plasma protein concentrations during WI, with plasma protein concentrations being lower (P Ͻ 0.05) in controls (decrease from 73.2 Ϯ 1.1 to 67.1 Ϯ 1.3 g/l, P Ͻ 0.05) than in HF patients (decrease from 80.7 Ϯ 1.6 to 75.2 Ϯ 1.8 g/l, P Ͻ 0.05).
Plasma potassium concentrations did not differ between groups, nor did they change in response to WI (controls from 4.1 Ϯ 0.08 to 4.2 Ϯ 0.06 mmol/l; HF patients from 3.9 Ϯ 0.10 to 4.0 Ϯ 0.11 mmol/l). Responses to 90 min of seated control. In the control subjects, systolic, diastolic, and mean arterial pressure increased slightly from 117 Ϯ 2, 80 Ϯ 3, and 92 Ϯ 3 mmHg, respectively, at the beginning of the 90-min seated control to 119 Ϯ 3, 83 Ϯ 3, and 96 Ϯ 3 mmHg (P Ͻ 0.05), respectively, during the last 15 min (Table  3) . In HF patients, systolic, diastolic, and mean arterial pressures varied insignificantly throughout the control session from 109 Ϯ 8 to 113 Ϯ 8 mmHg, from 75 Ϯ 4 to 78 Ϯ 4 mmHg, and from 86 Ϯ 5 to 89 Ϯ 5 mmHg, respectively. Cardiac index did not change during the 90 min of seated control (controls, from 1.82 Ϯ 0.1 to 2.00 Ϯ 0.1 l/m 2 ; HF, from 1.95 Ϯ 0.2 to 2.23 Ϯ 0.3 l/m 2 ), and no differences were observed between the groups (Table 3) . Heart rate did not change in controls (from 70 Ϯ 3 to 71 Ϯ 3 beats/min) and was lower than in HF (P Ͻ 0.05; Table 3 ). In HF patients, heart rate increased during the last 45 min of seated control from 86 Ϯ 5 to 91 Ϯ 5 beats/min (P Ͻ 0.05). Plasma sodium and potassium concentrations and plasma osmolality did not change over time. Plasma protein concentration increased slightly at the end of seated control in control subjects from 73.5 Ϯ 1.2 to 74.6 Ϯ 1.2 g/l (P Ͻ 0.05) but did not change in HF patients (from 80.1 Ϯ 2.0 to 80.9 Ϯ 2.2 g/l). Additional hemodynamic and neuroendocrine responses to 90 min of seated control are summarized in Table 3 .
DISCUSSION
The new information of this study is that central blood volume expansion and an increase in cardiac filling within the normal physiological range in compensated HF elicit a reduction in systemic vascular resistance similar to that in normal controls, despite blunted forearm vascular responses. Concomitantly, the release of AVP, renin, and NE is suppressed in HF patients to the same extent as in healthy subjects. Therefore, the baroreflex-mediated decrease in systemic vascular resistance and release of vasoactive hormones are dissociated from the reflex control of forearm vascular beds during WI-induced central blood volume expansion in HF. The hypothesis that suppression of the release of neuroendocrine mediators and the decrease in systemic vascular resistance would be attenuated in compensated HF in response to central blood volume expansion was therefore not confirmed.
The effects of upright seated central blood volume expansion by WI are probably different from those of whole body tilting from upright to supine, because in the supine position the transverse gravitational stress compresses the heart and thorax from back to front (42) . This might have a more pronounced effect on cardiac performance of the dilated ventricles in HF patients than in controls. During central volume expansion by seated WI, the gravitational compression of the thorax and heart is absent. We chose the upright seated position, because the upright body posture is the normal posture of humans during the daytime. Therefore, changing central blood volume by WI without changing body position may represent a more physiological stimulus than whole body tilting for investigating effects of central blood volume expansion on baroreflexes and vasoactive hormone release.
In HF patients and controls, central blood volume expansion augmented cardiac filling, improved cardiac performance, and increased stroke volume. The absolute increases in LAD and CVP in response to WI were very similar between HF patients and controls. The relative increase in LAD in response to central blood volume expansion, however, was less in HF patients (16 Ϯ 4%) than in the control subjects (27 Ϯ 5%), because the HF patients exhibited dilated cardiac chambers at baseline (as indicated by larger left atrial and left ventricular end-diastolic diameters). In the control subjects, systolic and arterial pulse pressures increased throughout WI; in HF patients, arterial pressure was unchanged during the initial 15 min, and systolic and mean arterial pressures increased only during the final 15 min of WI. Because stimulation of arterial baroreceptors is related to a change in arterial wall stretch (10) , it is difficult to exclude that arterial baroreceptor stimulation occurred, even in the absence of a detectable change in arterial pressures. In this experiment, the increase in stroke volume could have increased pulsatile vascular dimensions in the aorta, leading to an increase in aortic pulsatile stretch, a powerful stimulus to arterial baroreceptors (10) . It is therefore conceivable that cardiopulmonary and arterial baroreceptors were subjected to increased stretch in response to WI in HF patients and controls. Whether the receptors were stretched and/or stimulated to the same extent in HF patients and controls, however, cannot be deduced from this investigation.
Central blood volume expansion initiated a decrease in NE release and systemic vascular resistance from similar control levels in the two groups. This observation argues in favor of a preserved baroreflex-mediated inhibition of overall efferent sympathetic nervous activity in HF with a resultant vasodilatation. We expected elevated baseline levels of plasma NE and an attenuated suppression during WI in HF (21, 24) . Administration of digitalis glycosides (15) and ACE inhibition reduce efferent sympathetic nervous activity 
and enhance the sympathoinhibitory response to baroreceptor stimulation (5, 22) . Therefore, the normalized levels and responsiveness of plasma NE to WI in HF could be explained by the prior medical treatment and the fact that the patients were clinically stable in a compensated phase (NYHA class II-III). In addition, AVP and renin release were suppressed to the same extent in HF patients and controls in response to WI. The HF patients exhibited elevated baseline levels of plasma AVP, whereas plasma osmolality did not differ between HF patients and healthy controls. Therefore, nonosmotic release of AVP was apparently enhanced (2) . Central blood volume expansion initiated a normalized suppression of AVP release in HF, indicating that baroreceptor-mediated control of AVP release was well preserved in these HF patients.
The HF patients exhibited substantially elevated baseline levels of PRA and ANG II. The prior medical treatment, a relatively low sodium intake, increased efferent renal sympathetic nerve activity (8, 24) , and reduced renal blood flow (8) could have contributed to the elevated PRA. Suppression of PRA during WI in HF patients was similar to that of the control subjects, indicating that the response to an increase in central blood volume was preserved. The reduction in PRA during WI in HF did not cause a statistically significant reduction in plasma concentration of ANG II. Residual ACE inhibition or increases in pulmonary blood flow during WI may have perturbed the relationship between renin activity and generation of ANG II. This notion, however, remains to be investigated.
In contrast to the preserved decrease in systemic vascular resistance and suppression of NE, AVP, and renin release, the HF patients exhibited blunted reflex control of the forearm vascular beds and heart rate during WI and recovery. This is in compliance with previous observations that muscle sympathetic nerve activity and limb vascular responses are abnormal in HF in response to phlebotomy (33) , head-up tilt, or lower body negative pressure (19, 20, 27, 30, 33, 34, 43) and that HF patients demonstrate impaired control of heart rate in response to changes in baroreceptor stimulation (5, 10) .
There are several possible explanations for the coexistence of blunted forearm vascular and heart rate responses and the preserved decrease in systemic vascular resistance and release of neuroendocrine mediators. First, arterial baroreceptor modulation of efferent sympathetic activity seems to be well preserved in humans and experimental dog models of heart failure (1, 5, 6) , whereas cardiopulmonary modulation of efferent sympathetic outflow is markedly blunted (5, 7) . In healthy humans, cardiopulmonary baroreflexes modulate muscle sympathetic nerve activity and limb vascular resistance (10, 25, 32, 39) . Furthermore, several investigations indicate that simultaneous changes in cardiopulmonary and arterial baroreceptor stimulation must be present to modulate AVP and renin release (35, 39) . Therefore, the blunted forearm but preserved systemic vascular and neuroendocrine responses to WI in HF might be explained by a combination of relatively blunted low-pressure cardiopulmonary and preserved high-pressure arterial baroreflexes.
Second, if cardiopulmonary baroreflexes initiated the decrease in systemic vascular resistance and release of AVP and renin in HF, selective dysfunction of one cardiopulmonary baroreflex control mechanism (forearm) with the preservation of others (systemic vascular resistance and neuroendocrine responses) must have been present (33) . Further investigations, however, are needed to clarify this issue.
Third, the relative change in LAD in response to WI was less in HF patients than in controls. This could have caused less of a distension stimulus and resulted in an attenuated cardiopulmonary baroreflex engagement compared with controls and could explain the blunted forearm vascular responses.
A further understanding, however, of the degree of involvement of cardiopulmonary and arterial baroreceptors during WI is necessary to characterize their relative contributions to cardiovascular and neuroendocrine readjustments, respectively. Therefore, a definitive conclusion regarding the mechanism(s) of the dissociation of forearm vascular responses vs. the preserved neuroendocrine responses and decrease in systemic vascular resistance cannot be deduced from this study.
It has been recognized that increased parasympathetic activity to the heart elicited by arterial baroreceptor stimulation is the predominant mediator of the decrease in heart rate in response to a rapid hypervolemic/hypertensive stimulus (10, 31) . Because of the more prolonged (30 min) character of the hypervolemic immersion stimulus, it is conceivable, however, that inhibition of efferent sympathetic activity to the heart also contributes to the decrease in heart rate during immersion in healthy subjects. Therefore, the blunted decrease in heart rate observed in response to central volume expansion by WI in HF was probably caused by attenuated baroreflex control of parasympathetic (6) and sympathetic modulation of heart rate.
In HF patients, the forearm vascular responses to WI were more heterogeneous (increased, unchanged, and decreased) than in the control subjects, who exhibited uniform directional changes. Therefore, the variability (error bars in Fig. 2 ) of the measurements is different from that of the control subjects in response to WI. The variable response was probably due to the different degrees of HF, which are related to the degree of abnormal peripheral vascular response (43) . In contrast, systemic vascular resistance decreased in all HF patients and controls in response to WI. The variability between HF patients and controls (error bars in Fig. 2 ) was due to differences in individual levels of systemic vascular resistance. Furthermore, the CV of all these measurements did not differ in HF patients and controls during the 90-min seated control study (see METH-ODS; Table 3 ).
In the control subjects, the increase in central blood volume would have been expected to cause a decrease in forearm skeletal muscle vascular resistance in ad-dition to that of the subcutaneous vascular bed. In a recent investigation from our laboratory (unpublished observations), a decrease in forearm muscle vascular resistance could not be detected during WI to the xiphoid process, whereas an additional increase in central blood volume by WI to the neck caused skeletal muscle vasodilatation. Thus the volume stimulus by WI to the xiphoid process was apparently not sufficient to cause a detectable vasodilatation. Furthermore, the control subjects exhibited an increase in skeletal muscle vascular resistance during recovery from WI, whereas HF patients did not. These findings indicate that recovery from WI in controls was associated with an increase in forearm muscle sympathetic vasoconstrictor activity, whereas this was not observed in HF patients. The absence of skeletal muscle vasodilatation during WI may seem in contrast to the pronounced vasoconstriction during recovery. Baroreflex adaptation and/or resetting, however, may occur during the 30 min of WI. Therefore, WI and recovery may not elicit identical reciprocal changes in forearm muscle vasoconstrictor activity.
Baseline levels of ET-1 in HF patients were not different from those in controls. During WI and recovery, plasma ET-1 concentrations were slightly higher in HF patients than in controls. The (patho)physiological importance, however, of this minor difference is not clear. In HF, treatment with the ACE inhibitor fosinopril reduces elevated plasma ET-1 levels to normal values (18) . Therefore, treatment with ACE inhibitors could have normalized plasma levels of ET-1 in HF. Neither control subjects nor HF patients, however, exhibited any changes in plasma ET-1 in response to WI. Thus changes in plasma concentrations of ET-1 do not seem to explain the systemic vasodilatation in response to WI in HF patients and controls.
Limitations. The HF patients received prior medical treatment and were well compensated in NYHA class II-III without signs of elevated cardiac filling pressures, as indicated by the normal CVP at baseline. Because we measured CVP only in the upright seated position, it cannot be excluded that these patients exhibited elevated CVP in the supine position or elevated left-sided filling pressures. It is possible that HF patients with elevated cardiac filling pressures in the upright seated position and/or without the prior medical treatment may have exhibited a response to WI that was different from that of the subjects investigated in this study.
We do not know whether forearm vascular responsiveness was altered in HF. Results of previous investigations indicate, however, that abnormal forearm vascular and sympathetic nerve activity responses to changes in baroreceptor stimulation in HF are caused by impaired afferent and/or central nervous system baroreflex mechanisms, because the efferent limbs of these responses are preserved during generalized sympathetic activation by the cold pressor test (33, 37) . It is therefore unlikely that altered end-organ responsiveness contributed to the blunted forearm vascular responses in HF.
Conclusions. The results of this study demonstrate that central blood volume expansion in compensated HF elicits a reduction in systemic vascular resistance similar to that of normal control subjects, despite blunted forearm vascular responses. Concomitantly, release of AVP, renin, and NE is suppressed in HF patients to the same extent as in healthy subjects. Thus the baroreflex-mediated decrease in systemic vascular resistance and in release of vasoactive hormones is dissociated from the reflex control of forearm vascular beds and heart rate in compensated HF during WI-induced central blood volume expansion.
Perspectives. The increase in central blood volume improved cardiac performance, decreased sympathetic nerve activity and systemic vascular resistance, and suppressed the release of vasoactive and sodium-and water-retaining hormones in compensated HF. In fact, WI tended to normalize the levels of these variables. Therefore, the effects of WI on renal sodium and water handling in HF should be addressed in future studies. Such investigations may provide further insight into the pathophysiology of extracellular fluid volume control and may have implications for the treatment of HF.
Several investigators have demonstrated abnormal forearm vascular responses to head-up tilt and lower body negative pressure in HF. The results of the present investigation indicate that changes in forearm vascular resistance do not always reflect changes in systemic vascular resistance in HF. Because systemic vascular resistance is more important than forearm vascular resistance in determining arterial pressure and/or cardiac afterload in HF, future studies should also focus on the regulation of this variable.
